THE PRODUCT REGULATION AND LIABILITY REVIEW

FOURTH EDITION

Editors
Chilton Davis Varner and Bradley W Pratt
THE TAX DISPUTES AND LITIGATION REVIEW
THE LIFE SCIENCES LAW REVIEW
THE INSURANCE AND REINSURANCE LAW REVIEW
THE GOVERNMENT PROCUREMENT REVIEW
THE DOMINANCE AND MONOPOLIES REVIEW
THE AVIATION LAW REVIEW
THE FOREIGN INVESTMENT REGULATION REVIEW
THE ASSET TRACING AND RECOVERY REVIEW
THE INSOLVENCY REVIEW
THE OIL AND GAS LAW REVIEW
THE FRANCHISE LAW REVIEW
THE PRODUCT REGULATION AND LIABILITY REVIEW
THE SHIPPING LAW REVIEW
THE ACQUISITION AND LEVERAGED FINANCE REVIEW
THE PRIVACY, DATA PROTECTION AND CYBERSECURITY LAW REVIEW
THE PUBLIC-PRIVATE PARTNERSHIP LAW REVIEW
THE TRANSPORT FINANCE LAW REVIEW
THE SECURITIES LITIGATION REVIEW
THE LENDING AND SECURED FINANCE REVIEW
THE INTERNATIONAL TRADE LAW REVIEW
THE SPORTS LAW REVIEW
THE INVESTMENT TREATY ARBITRATION REVIEW
THE GAMBLING LAW REVIEW
THE INTELLECTUAL PROPERTY AND ANTITRUST REVIEW
THE REAL ESTATE M&A AND PRIVATE EQUITY REVIEW
THE SHAREHOLDER RIGHTS AND ACTIVISM REVIEW
THE ISLAMIC FINANCE AND MARKETS LAW REVIEW
THE ENVIRONMENT AND CLIMATE CHANGE LAW REVIEW
THE CONSUMER FINANCE LAW REVIEW

www.TheLawReviews.co.uk
ACKNOWLEDGEMENTS

The publisher acknowledges and thanks the following law firms for their learned assistance throughout the preparation of this book:

AFE BABALOLA SAN & CO (EMMANUEL CHAMBERS)
AZB & PARTNERS
BAKER MCKENZIE WONG & LEOW
CLAYTON UTZ
CMS RUSSIA
ESTUDIO BECCAR VARELA
HEUKING KÜHN LÜER WOJTEK
INTUITY
KING & SPALDING LLP
KING & WOOD MALLESONS
KYRIAKIDES GEORGOPOULOS LAW FIRM
LINKLATERS LLP
MATTOS FILHO, VEIGA FILHO, MARREY JR E QUIROGA ADVOGADOS
NISHIMURA & ASAHI
PAUL HASTINGS (EUROPE) LLP
THE PRATT LAW FIRM, PC
SEPULVADO & MALDONADO, PSC
S HOROWITZ & CO
URÍA MENÉNDEZ
VIEIRA DE ALMEIDA & ASSOCIADOS – SOCIEDADE DE ADVOGADOS, RL
# CONTENTS

PREFACE............................................................................................................................................................ v

*Chilton Davis Varner and Bradley W Pratt*

Chapter 1  ARGENTINA........................................................................................................................ 1

*Ignacio Flores and Gonzalo Garcia Delatour*

Chapter 2  AUSTRALIA.............................................................................................................................. 11

*Colin Loveday and Sheena McKie*

Chapter 3  AUSTRIA............................................................................................................................. 24

*Eva Spiegel and Gabriele Hintsteiner*

Chapter 4  BELGIUM............................................................................................................................. 35

*Joost Verlinden and Gert-Jan Hendrix*

Chapter 5  BRAZIL................................................................................................................................. 45

*Fabio Teixeira Ozi and Murilo Castineira Brunner*

Chapter 6  CHINA................................................................................................................................. 56

*Ariel Ye, Yue Dai and Xinyu Li*

Chapter 7  ENGLAND & WALES........................................................................................................... 66

*Fiona East*

Chapter 8  FRANCE................................................................................................................................ 77

*Christophe Hénin*

Chapter 9  GERMANY............................................................................................................................ 91

*Christoph Wagner*

Chapter 10  GREECE............................................................................................................................. 104

*Anthony B Hadjioannou and Maria S Kanellopoulou*
<table>
<thead>
<tr>
<th>Chapter</th>
<th>Country</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>11</td>
<td>INDIA</td>
<td>Vivek Bajaj and Annie Philip</td>
</tr>
<tr>
<td>12</td>
<td>ISRAEL</td>
<td>Avi Ordo and Moran Katz</td>
</tr>
<tr>
<td>13</td>
<td>ITALY</td>
<td>Francesca Petronio and Francesco Falco</td>
</tr>
<tr>
<td>14</td>
<td>JAPAN</td>
<td>Akihiro Hironaka, Yutaro Kawabata and Yui Takahata</td>
</tr>
<tr>
<td>15</td>
<td>NIGERIA</td>
<td>Afe Babalola SAN</td>
</tr>
<tr>
<td>16</td>
<td>PORTUGAL</td>
<td>Ana Lickfold de Novaes e Silva and Pedro Pires Fernandes</td>
</tr>
<tr>
<td>17</td>
<td>PUERTO RICO</td>
<td>Albéniz Couret-Fuentes and Elaine M Maldonado-Matías</td>
</tr>
<tr>
<td>18</td>
<td>RUSSIA</td>
<td>Sergey Yuryev</td>
</tr>
<tr>
<td>19</td>
<td>SINGAPORE</td>
<td>Lim Ren Jun</td>
</tr>
<tr>
<td>20</td>
<td>SPAIN</td>
<td>Alex Ferreres Comella and Cristina Ayo Ferrándiz</td>
</tr>
<tr>
<td>21</td>
<td>SWITZERLAND</td>
<td>Frank Scherrer, Caroline Müller Tremonte and Caspar Humm</td>
</tr>
<tr>
<td>22</td>
<td>UNITED STATES</td>
<td>Chilton Davis Varner and Bradley W Pratt</td>
</tr>
<tr>
<td>Appendix</td>
<td>ABOUT THE AUTHORS</td>
<td></td>
</tr>
<tr>
<td>Appendix</td>
<td>CONTRIBUTING LAW FIRMS’ CONTACT DETAILS</td>
<td></td>
</tr>
</tbody>
</table>
In today’s global economy, product manufacturers and distributors face a dizzying array of overlapping and sometimes contradictory laws and regulations around the world. A basic familiarity with international product liability is essential to doing business in this environment. An understanding of the international framework will provide thoughtful manufacturers and distributors with a strategic advantage in this increasingly competitive area. This treatise sets out a general overview of product liability in key jurisdictions around the world, giving manufacturers a place to start in assessing their potential liability and exposure.

Readers of this publication will see that each country’s product liability laws reflect a delicate balance between protecting consumers and encouraging risk-taking and innovation. This balance is constantly shifting through new legislation, regulations, treaties, administrative oversight and court decisions. But the overall trajectory seems clear: as global wealth, technological innovation and consumer knowledge continue to increase, so will the cost of product liability actions.

This edition reflects a few of these trends from 2016. Notably, many jurisdictions saw an increase in both mandatory and voluntary product recalls across various industries. In India, for instance, several global car manufacturers initiated voluntary recalls of vehicles owing to various product defects, such as emissions systems that violated environmental norms. This unprecedented rise in voluntary vehicle recalls spawned legislation known as the Motor Vehicles Amendment Bill, currently pending approval in the Indian Parliament, that would for the first time mandate vehicle recalls under certain conditions. Several jurisdictions also saw a proliferation of class actions in product liability contexts. In July, the Collective Claims Act came into force in Japan, enabling small consumer claims to be aggregated and pursued by ‘certified organisations’, which are required to disburse to consumers 50 per cent or more of the claims recovered from business operators. This edition also highlights how certain countries’ product liability laws have grappled with novel issues in the modern economy, ranging from e-commerce (e.g., the Brazilian Superior Court of Justice’s conclusion that internet search providers cannot be held liable for defective products marketed through their websites) to emerging technologies (e.g., Australia’s interim ban on self-balancing scooters or ‘hoverboards’). Although these changes and trends may be valuable in their own right, they also create a need for greater vigilance on the part of manufacturers, distributors and retailers.

This edition covers 22 countries and territories and includes a high-level overview of each jurisdiction’s product liability framework, recent changes and developments, and a look forward at expected trends. Each chapter contains a brief introduction to the country’s product liability framework, followed by four main sections: regulatory oversight (describing the country’s regulatory authorities or administrative bodies that oversee some aspect of
product liability); causes of action (identifying the specific causes of action under which manufacturers, distributors or sellers of a product may be held liable for injury caused by that product); litigation (providing a broad overview of all aspects of litigation in a given country, including the forum, burden of proof, potential defences to liability, personal jurisdiction, discovery, whether mass tort actions or class actions are available and what damages may be expected); and the year in review (describing recent, current and pending developments affecting various aspects of product liability, such as regulatory or policy changes, significant cases or settlements and any notable trends).

Whether the reader is a company executive or a private practitioner, we hope that this edition will prove useful in navigating the complex world of product liability and alerting you to important developments that may affect your business.

We wish to thank all of the contributors who have been so generous with their time and expertise. They have made this publication possible. We also wish to thank our colleagues Madison Kitchens and Jordan Raymond, who have been invaluable in assisting us in our editorial duties.

Chilton Davis Varner and Bradley W Pratt
King & Spalding and The Pratt Law Firm
United States
March 2017
I INTRODUCTION TO THE PRODUCT LIABILITY FRAMEWORK

In the Spanish legal system, product liability regulations were to be found, until 2007, in Article 1902 of the Civil Code (CC), which used to set out the rules concerning liability in tort, in the General Law for the Protection of Consumers and Users and in the Defective Products Liability Act, which transposed the EEC Directive of 25 July 1985 concerning Liability for Defective Products (the 85/374 Directive).

The moment at which the product had been put into circulation determined which particular set of rules applied. For these purposes ‘putting into circulation’ meant the voluntary delivery of the product by the manufacturer, which, for practical purposes, meant distributing the product or making it available to the relevant persons.

Under the Defective Products Liability Act’s final provision, this Act applied to those instances of product liability in which the relevant product had been put into circulation after 8 July 1994 (i.e., on the day following the coming into force of the Defective Products Liability Act). The General Law for the Protection of Consumers and Users applied to any products put into circulation between 13 August 1984 and 8 July 1994 and, finally, Article 1902 of the CC applied to any products put into circulation before the coming into force of the General Law for the Protection of Consumers and Users, that is, before 13 August 1984.

Note that where one particular set of rules applied the rest did not and, as has just been stated, the moment at which a product had been put into circulation determined which set of rules applied.

The rules differed in such matters as the identification of the person responsible, the circle of possible injured persons and the damages covered. However the underlying purpose of all those sets of rules and the definition of a defective product were the same. The latter was explicitly addressed in the 85/374 Directive and the Defective Products Liability Act (which, as indicated, transposed the 85/374 Directive).

The diversity of product liability regimes came to an end by virtue of the coming into force of Royal Legislative Decree 1/2007, which enacted the Consumers and Users Protection (Consolidation) Act and other complementary regulations.

Both the General Law for the Protection of Consumers and Users and the Defective Products Liability Act (among other consumer protection regulations) were repealed following their consolidation into Royal Legislative Decree 1/2007. This means that Royal

---

1 Alex Ferreres Comella is a partner and Cristina Ayo Ferrándiz is a counsel at Uría Menéndez.
Legislative Decree 1/2007, which does not substantially differ from the Defective Products Liability Act (and therefore follows the guidelines laid down by the 85/374 Directive), is currently the only set of rules applicable to liability for defective products.

The Third Transitory Provision of Royal Legislative Decree 1/2007 provides for specific rules applicable to any product put into circulation before 8 July 1994 (i.e., before the coming into force of the Defective Products Liability Act). However, a scenario calling for the application of such transitory rules is highly unlikely to arise. This is because under Section 144 of Royal Legislative Decree 1/2007, the liability of manufacturers expires after 10 years as of the date on which the product was put into circulation, as was the case under Section 14 of the Defective Products Liability Act.

II REGULATORY OVERSIGHT

Although Royal Legislative Decree 1/2007 contains some provisions regarding general safety of products, it is Royal Decree 1801/2003 concerning general product safety that transposed into Spanish law the EU General Product Safety Directive (2001/95/CE), the main and general regulation in safety issues.

Like the Directive, Royal Decree 1801/2003 is a general and horizontal, non-contractual regulation on general product safety, applicable to all product types put into circulation in Spain. Pursuant to this regulation, only safe products can be put into circulation on the Spanish market.

The National Agency on Consumption and Food and Nutrition Safety (AECOSAN)\(^2\) is the regulator, with nationwide competence, and the regional authorities are competent\(^3\) within their own territories.

However, it must be noted that this regulation will only apply to all product types in the absence of any specific existing regulation. Indeed, there are some specific products (food, cosmetics or medicines, for instance) that have specific safety regulation and sometimes need prior administrative approval to be put on the market.

Likewise, the AECOSAN will be competent provided that there is no specific body in charge of the safety of specific products (such as the Spanish Agency of Medicines and Medical Devices (AEMPS)).

---

2 The National Consumption Institute was the competent regulator. Owing to recent restructuring, the National Consumption Institute was merged with the Spanish National Agency on Food and Nutrition Safety to create the AECOSAN.

3 Dirección General de Consumo, in Andalucia; Dirección General de Consumo, in Aragón; Agencia de Sanidad Ambiental y Consumo in Asturias; Dirección General de Consumo in the Balearic Islands; Dirección General de Comercio y Consumo, in the Canary Islands; Dirección General de Comercio y Consumo, in Cantabria; Agencia de Protección Civil and Consumo, in Castilla and León; Instituto de Consumo de Castilla-La Mancha, in Castilla La Mancha; Agencia Catalana de Consumo, in Catalonia; Consejería de Sanidad and Consumo, in Ceuta; Instituto de Consumo de Extremadura, in Extremadura; Instituto Gallego de Consumo, in Galicia; Dirección General de Salud Pública and Consumo, in La Rioja; Dirección General de Consumo, in Madrid; Dirección General de Sanidad and Consumo, in Melilla; Dirección General de Atención al Ciudadano, Drogodependencias and Consumo, in Murcia; Dirección General de Familia, Infancia and Consumo, in Navarra; Dirección de Consumo, in the Basque Country; Dirección General de Comercio and Consumo, in Valencia.
III CAUSES OF ACTION

Taking into consideration the regulations noted above, the following are the causes of action when putting a product into circulation.

i Civil law

Royal Legislative Decree 1/2007

A product is deemed to be defective where it does not sufficiently guarantee the safety that is expected of it.

In order to establish whether a given product is or is not defective, it must satisfy the non-safety test. Other tests, including that of substandard quality or unfitness for purpose, do not apply.

Royal Legislative Decree 1/2007 does not draw a distinction among the three types of defects traditionally identified by legal scholars:

a manufacturing defects that arise from flaws in the manufacturing process and often affect individual products within the same series;

b project or design defects that arise from flawed technical designs prior to manufacture (that is, at the technical ideation stage of the product) and often affect all of the units manufactured; and

c information defects that arise from flawed, incomplete or insufficient information that misleads consumers as to the manner in which a given product should be used or its degree of safety.

As for information defects it may be argued that, by using the degree of safety test in order to establish whether a product is or is not defective, the law actually calls for an assessment of the extent to which the potential risks associated with a particular product are known. In this way, a product will be regarded as defective when it falls short of providing the safety expected of it or, to put it differently, when it does not provide the safety that consumers expect.

Conversely, no liability will arise where the risks associated with a given product are known by the injured person as, in these circumstances, the fact that a product is not safe is part and parcel of what is to be expected from the relevant product (theory of assumed risks). This may occur because (1) such risks are obvious (e.g., a knife or a pair of scissors are cutting instruments), because (2) such risks are socially and culturally known by the public (e.g., risks associated with tobacco or alcohol consumption), or because (3) the manufacturer, in compliance with its duty to provide the necessary information about its product, had provided to the injured persons adequate instructions for its use and information about the risks associated with such use.

Clearly, safety expectations are to be assessed from an objective standpoint and by having regard to the average individual’s knowledge and to the manufacturer’s lawful expectations about use. The subjective perspective of the particular injured person must be disregarded for these purposes.

Both the 85/374 Directive and Royal Legislative Decree 1/2007 provide that the product presentation, the reasonable use of the product, and the moment of its putting into circulation are criteria that must be taken into account to establish the expectations that injured persons could properly have of the relevant product.
The scope is limited to the liability of producers and suppliers exclusively for bodily harm sustained as a result of the use or consumption of a defective product and for damage caused to things other than the product itself, provided that the defective product itself was meant for private consumption (i.e., not intended for professional use).

Any other type of damage (moral or over the product itself) must be sought under general civil regulation.

Royal Decree 1801/2003
Under Royal Decree 1801/2003, only safe products can be put into circulation on the Spanish market. This means that each party in the distribution chain must take appropriate measures to ensure that all products are safe; and where any party knows that a product already put into circulation is not safe, it must take appropriate corrective measures.

A product will be considered safe provided that, under normal and reasonable conditions of use, it does not present any risk or presents only such risks that are acceptable and compatible with the intended use of the product, taking into consideration circumstances such as the characteristics of the product, any information provided with it, or the consumer it is directed towards.

Royal Decree 1801/2003 also sets out a presumption that a product is safe when it has been produced in accordance with Spanish or European compulsory regulations on health and safety or, where no specific regulation exists, in accordance with Spanish standards (UNE standards), European Commission recommendations, or the current state of the art, for instance that the state of scientific and technical knowledge at the time of putting into circulation was not such as to enable the existence of the defect to be discovered.

Conversely, Royal Decree 1801/2003 presumes that a product is not safe when it has been produced without CE or EC marks, or whenever a product has been produced without passing any compulsory authorisations or controls.

This regulation applies basically over producers and distributors, although it is also applicable over any party in the production and distribution chain.

ii Criminal law
Criminal law provides for certain crimes in the field of product liability. Causing risk to persons (without it being necessary for such risk to have materialised in harm to specific persons) by placing medicines and products intended for human consumption on the market, whether by violating safety or health regulations or by unauthorised adulteration or handling, is defined as a crime against public health. In cases other than those involving the manufacture and marketing of medicines and products intended for human consumption, the damage caused by a defective product can be characterised as a crime of homicide or of injury, in both cases owing either to gross or to ordinary negligence, provided that the violation may be qualified as criminal depending on the importance of the safety rules that have been violated.

IV LITIGATION
i Forum
Civil procedure is regulated by the Spanish Civil Procedural Act enacted on 7 January 2000.
The Spanish legal system is unitary and uniform throughout the territory. This means that its courts are organised in territorial terms into provincial districts, each of which groups together several geographical areas, which, in turn, comprise several municipalities.

The lowest level of the civil jurisdiction is made up of the courts of first instance, which are formed each by one single judge. In general, these courts hear in the first instance all proceedings to which the parties are private individuals and companies, and they are almost exclusively in charge of hearing and examining evidence and pleadings submitted by the parties and, subsequently, of rendering their judgments.

The provincial court of appeal hears appeals against decisions rendered by the courts of first instance. There is a provincial court of appeal in each of the 50 provinces that make up the Spanish territory, and in populous provinces such court is divided into several sections, each sitting with three magistrates.

Apart from the Superior Court of Justice, which is the highest court of each of the autonomous communities into which the Spanish territory is divided and, basically, are in charge of hearing motions for dismissal in connection with specific matters of law of their own and respective autonomous community, the Supreme Court is the highest court in product liability cases, although some issues might be brought before the Constitutional Tribunal.

In product liability cases, the jurisdictional function, both in terms of fact-finding and of the legal declaration of liability, corresponds exclusively to the judges and the courts. Jury courts before which some crimes are tried do not have jurisdiction over product liability cases.

Furthermore, in Spain, there are two basic declarative procedures for seeking payment of compensation: the verbal proceeding or the ordinary proceedings. Which stream a case falls under will depend on the amount claimed: (1) seeking payment of compensation of up to €6,000 is handled in verbal proceedings, and (2) for cases where the amount claimed is more than €6,000, the claim is handled in ordinary proceedings.

In both cases, the civil procedure starts with the filing of the claim. The claim must include all factual allegations on which it is based, in as much detail as possible, as well as the legal grounds on which it is based. However, under the principle of *jura novit curia*, (1) the plaintiff is not required to set out the legal grounds in thorough detail, and (2) the legal grounds claimed are not binding upon the judge, who may uphold the action based on alternative legal grounds.

If verbal proceedings are initiated, once the claim has been filed and given leave to proceed, the defendant is notified so that he or she may present a defence (or a counterclaim brief) within a term of 10 working days (which includes all days of the year except Saturday, Sundays, national holidays, non-working days in the autonomous region and/or city where the proceedings take place, and the month of August).4

Subsequently, the court will call the parties to a hearing in which they propose the evidence they are going to submit, the evidence is produced and, if the court deems it necessary, final conclusions are presented.

---

4 Until very recently, the main difference between verbal and ordinary proceedings was that in verbal proceedings the plaintiff used to file a written lawsuit, while the defendant did not file a written response to the lawsuit. In this type of proceedings, the court summoned the parties to a hearing where the defendant presented its response orally and the evidence was submitted. However, this has been recently modified in the Spanish Procedural Act and in verbal proceedings the brief of response is also submitted in writing.
If ordinary proceedings are initiated, once notified of the lawsuit, the defendant will have a 20-working day time period to file the brief of response. Subsequently, the court will call the parties to a preliminary hearing in which they propose the evidence they are going to submit, and, finally, the court calls the parties to the trial where the evidence and final conclusions are presented. In this case, therefore, there are two different hearings.

ii  Burden of proof

The general principle that the burden of proof of a factual allegation lies on the person who makes the allegation is one that presides over the Spanish legal system.

In accordance with the general civil liability regime under Royal Legislative Decree 1/2007, the party claiming product liability must provide evidence of the existence of a defect in the product, of the damage or injury, and of the causal relationship between the two.

In Spain, the standard of proof of that causal link is in theory high. The Supreme Court formally requires that evidence of the existence of a causal link must be clear and precise, and not based on mere deduction, conjecture or probability. Therefore, in principle, it requires absolute evidential certainty.

Consequently, in Spain, tests applied elsewhere like the ‘more probable than not’ rule are, in theory, not applicable. And statistics or epidemiology do not appear to be sufficient by themselves to prove a causal link.

In practice, however, judges and courts often reach decisions in a manner that comes close to applying the ‘more probable than not’ rule, in particular, through recourse to the judicial presumption, whereby the judge or court applies human logic rules to deduce a fact and deems it proven (deduced fact) on the basis of the evidence of one or more basic facts.

On other occasions, the courts have determined the causal relationship by reference to statistics and epidemiology – which are deemed to be insufficient by themselves to establish the causal link – in combination with other basic facts.

The ruling on the rapeseed oil case is an illustrative example of the use of epidemiological studies by the Spanish Supreme Court. Although the events took place in 1981, the Supreme Court did not issue a final judgment on this case until 26 September 1997.

In that case, the Supreme Court found that (1) a link between the consumption of rapeseed oil and the disease suffered by more than 20,000 injured parties had been epidemiologically determined; (2) the pathology found in the injured parties was new (it had never before been diagnosed) and consequently no risk factors inherent to the disease had been identified by the scientific community; (3) none of the parties to the proceedings proposed any alternative causal hypothesis other than the consumption of rapeseed oil; and (4) once the denatured rapeseed oil was removed from the market and its consumption had been suspended, no new cases of intoxication were diagnosed.

Importantly, epidemiology was not considered in itself to be sufficient proof of a causal relationship. Epidemiology was just one more link in the Supreme Court’s logical reasoning chain that led to the evidential conclusion of the existence of a causal relationship.

iii  Defences

Royal Legislative Decree 1/2007 specifically provides for the statutory limitation of actions brought by virtue of this law within a term of three years of the time the victim sustained the injury or damages.

It also provides that the rights of the victim will lapse 10 years after the date the product was put into circulation (provided that no legal action has been instigated in that period).
In relation to the start of the computation of the limitation period, Article 1969 of the Civil Code provides that ‘the time limit for all sort of legal actions, when not otherwise provided for under a special provision, will start on the day that such actions may be brought.’ As for the time when the case is deemed to be actionable, it has been chiefly understood to be identified with the time when the injured party learned of the damage or injury sustained (‘from the time the aggrieved party learned of it’, as noted under Article 1968.2 of the Civil Code).

This criterion regarding the start of the time limit is also applied within the product liability context: ‘from the date the injured party sustained the injury or damage’.

In any consideration of limitation periods, the Spanish courts tend to lean generously in favour of the interests of the plaintiffs.

Apart from the statute of limitations defence, Royal Legislative Decree 1/2007 provides that manufacturers or importers are not liable, as long as evidence of any of the following circumstances is provided:

a. the product was not put into circulation by the relevant manufacturer or importer;
b. having regard to the circumstances, it was to be expected that no defect existed at the time at which the product was put into circulation;
c. the product was not manufactured for sale or for any other method of distribution for an economic purpose, or was neither manufactured nor imported, supplied or distributed in the course of a professional or business activity;
d. the defect was the result of manufacturing the product in accordance with mandatory rules in force; or

e. the state of scientific and technical knowledge at the time of putting into circulation was not such as to enable the existence of the defect to be discovered (i.e., the ‘state-of-the-art’ defence).

Under this exemption-of-liability clause, damages caused by a defective product are not amenable to compensation where the state of scientific or technical knowledge at the time the damage was caused was not such so as to avoid such damage.

Therefore, manufacturers whose production activity adheres to the scientific and technical knowledge available at the time of putting their products into circulation will be relieved of liability provided that the state of scientific and technical knowledge was not such so as to allow the discovery of the defect.

Some scholars suggest that reliance on generally known empirical knowledge is not enough for manufacturers to successfully prove this exemption of liability cause. Manufacturers need also to ensure that they rely on state of the art scientific knowledge and research. This is tantamount to an implicit duty on the part of manufacturers to conduct research into the safety of their products whatever the manufacturer’s turnover, market position or financial resources.

There are two product types where manufacturers will be liable despite having conducted their activity in accordance with the state of scientific and technical knowledge available at the time of putting their products into circulation: drugs and foodstuffs meant for human consumption. This means that the law imposes a more stringent and direct duty to conduct research into the safety of these products.
In addition to the grounds for exoneration listed above, Royal Legislative Decree 1/2007 also contemplates the possibility that a manufacturer's liability may be reduced owing to the intervention of third parties or of the injured party, and in the latter case the manufacturer's liability may not arise at all.

Indeed, if a third party has intervened in the manufacturing of the product, the manufacturer who would have paid any applicable indemnity sum would be entitled, by means of a 'recovery or repetition action', to recover from such third party that party's share of the cost of the damage.

With regard to intervention by the injured party (fault of the victim), the manufacturer must prove that the damage would not have occurred without the injured party’s intervention, or that the injury or damage caused would, at least, not have been so serious.

iv  Personal jurisdiction

As a member of the EU, Spain is subject to the provisions set out in Article 7.2 of the Council Regulation 1215/2012, on jurisdiction, recognition and enforcement of judgments in civil and commercial matter. Under that article, any person who has suffered damages as a consequence of a defective product can sue any EU manufacturer before the courts of the country where the harmful event has occurred or may occur. That will normally coincide with the courts of the claimant's own domicile.

The same rule is set out in Spanish law in connection with cases involving non-EU manufacturers. Therefore, foreign manufacturers are subject to Spanish jurisdiction provided that the damages caused by the defective product have been caused within the Spanish territory.

However, where the product has not been manufactured in Spain, and has not been sold or advertised in Spain, but the injury occurs within the Spanish territory, it may be argued that the harmful event has not properly occurred in Spain (i.e., while damage as such will have occurred in Spain, the harmful effect – the putting into circulation of a defective product – may not be understood to have occurred therein).

v   Expert witnesses

The Spanish Civil Procedural Act provides for the expert witness who is a person having the technical, scientific, artistic or practical knowledge of the relevant issue, as well as the direct knowledge or news of the facts or events as a witness.

As a general rule, experts’ reports should be filed together with the initial writs of claim and of defence; however, a number of exceptions are set for cases where special circumstances exist.

Thus, if a plaintiff shows that the proper defence of his or her rights prevented him or her from delaying the filing of his or her claim, he or she may submit an expert report subsequently, provided that he or she announces it in the writ of claim and the report is filed prior to the pretrial hearing. Logically, this possibility is absolutely limited, in principle, to cases of statutory limitations taking into consideration that the defendant has only 20 working
days to file the brief of response, it can file it five days prior to the preliminary hearing, provided that it justifies that it could not be obtained before the expiration of the term provided by law to file the defence brief and it announces its filing in the brief of response.

If the need for expert witness evidence becomes manifest in view of the pleadings contained in the defendant’s writ of defence, or in view of the complementary pleadings made by any of the parties prior to or at the preliminary hearing, the parties may provide any such expert witness report until five days before the start of the trial.

Moreover, any of the parties may prefer to request from the court the appointment of an expert but it should do so, expressly, in its initial writ.

In principle, expert reports, as any other mean of evidence, must be proposed by the parties; however, the law provides that the appointment of an expert by the court can also be requested when the need for expert testimony becomes evident either in view of the pleadings contained in the writ of defence (in which case only the plaintiff may request it) or in view of any complementary pleadings by any of the parties before or at the preliminary hearing.

vi Discovery

The Spanish legal system does not provide for a general disclosure procedure. However, the law does provide for coercive measures in relation to document disclosure only in two specific situations.

In the event that preliminary proceedings\(^6\) have commenced, the law provides for the possibility for the court to enter and to search premises in order to obtain certain documents requested by the plaintiff, in cases where the person or entity to which they refer or who are in possession of such documents, refuses to disclose them.

During the ordinary proceedings, the law provides for the possibility to request from the other parties disclosure of documents referring to the object of the proceedings.\(^7\) Should the party or parties unjustifiably refuse to disclose the requested private documents, the court may either (1) attribute to such document the evidential value alleged by the requesting party, or (2) issue an express injunction for the documents to be furnished, when it is deemed advisable given the nature of the documents, of the other evidence brought to the proceedings and of the contents of the allegations and claims made.

However, unlike for the preliminary proceedings, here the law does not provide for the entry and search of premises in the event of a refusal of document disclosure. However, the party who refuses to disclose documents required by the court may be in contempt of court, which is characterised as a criminal offence.

vii Apportionment

Spanish courts may apportion liability in those cases in which several agents have contributed to the damaging event, it being possible to determine the specific level contribution of each of those; however, market share liability has not yet been applied by the Spanish courts.

\(^6\) This is an exceptional procedure, simply aimed at preparing the proceedings (and therefore, prior to filing the lawsuit) whose purpose is for the potential plaintiff to verify the suitability of the defendant and the object of the claim.

\(^7\) The requesting party must in such cases provide a simple copy of the requested document or, in the absence thereof, indicate the contents of the requested document in the most accurate terms possible.
On the contrary, in those cases in which it is not possible to determine the specific level of contribution of each agent to the damaging event (while it is certain that all of them have to some – unknown – extent contributed to it), courts may find all the agents liable jointly and severally.

In the case of merger or acquisition of the manufacturing company, the beneficiary of the merger or acquirer undertakes any potential product liability incurred by the acquired company as a result of its manufacturing and putting into circulation of unsafe products. The mentioned succession on liability does not occur, however, where a company purchases a brand or a production line of producer, but the producer continues to exist as such.

viii Mass tort actions

The Spanish Civil Procedure Act instituted a system of collective actions whereby certain consumer associations can exercise a legal action on behalf of (1) either a determined (or easily determinable) or (2) undetermined number of consumers who have sustained injuries or suffered a loss as a consequence of consuming a product or using a service.

The Civil Procedure Act states that if the number, identity and specific circumstances of the aggrieved consumers are determined or are easily determinable at the declaratory stage of the proceedings, both the consumer associations and the groups of aggrieved consumers by themselves (i.e., they do not need to be represented by a consumer association) hold capacity to sue on behalf of all the aggrieved consumers. In this regard, the group is considered to be legally constituted as the representative plaintiff (i.e., as the plaintiff in the proceedings) when at least 50 per cent of its members have joined it.

In turn, only the consumer associations that are members of the Spanish National Consumer Committee have legal standing to file legal actions on behalf of an undetermined number of consumers.

Although the specific requirements that a collective claim must fulfil in order to be accepted (as it happens with the class actions) are not regulated, the Civil Procedure Act requires that the damaging event be the same.

In the case of joinder of actions, which also exist in the Spanish regulations, a plaintiff can aggregate different legal actions against different defendants provided that the issues of fact that underlie each of the actions are sufficiently common. Pursuant to this regulation, the damaging event does not need to be the same, but there must be a connection between actions. Taking into consideration that each case can be somehow different, although must be connected, the limit of this type of action is the procedural economy principle.

ix Damages

The Spanish civil liability system is based on compensatory grounds. Consequently, indemnifiable damages should match the impairment or loss suffered by a person as a result of a given event or fact, whether such impairment or loss affects the person’s natural vital attributes or his or her property or assets.

Indemnifiable damages include both the strictly economic damages and also ‘non-material damages’ (including, for instance, suffering or pain).8

---

8 ‘Non-material damages’ are not economically assessable, although compensation for such damage is imposed by law. In practice, each court determines the economic value of such non-material damage according to each specific case, and this is generally proportional to the strictly economic damages that are granted.
Punitive damages are not contemplated in the Spanish legal system. Royal Legislative Decree 1/2007 establishes an accrued liability limit of €63,106,270.96 (this is a global civil liability for producers for death and personal damages caused by identical products affected by the same defect).

Damages in respect of the cost of medical monitoring can be recovered. Additionally, according to the Spanish laws on torts, nothing prevents a claimant from seeking compensation in kind (\textit{in natura} as opposed to monetary compensation). In this regard, to the extent that it could be understood as a means of compensation in kind in connection with mental damage (suffering or anxiety), medical monitoring might be accepted as a form of compensation.

V YEAR IN REVIEW

Some consumers’ and users’ associations in Spain announced the initiation of a collective action against some vehicle manufacturers in order to claim economic compensation for those affected by the emissions scandal. For the moment no collective action seems to have yet been filed, although some individual cases have already been lodged and in fact decided differently depending on the specific circumstances of the case, which can be used as a test case for any collective action.

In any case, the pharmaceutical industry continues to be a target of many of the most significant product liability claims in Spain. Recently, the Spanish Supreme Court issued a decision on a product liability case in the aviation sector. The relatives of more than 100 passengers and crew who were killed when two aircraft in which they were travelling collided over Germany in 2002 filed a product liability claim against two companies that had supplied the anti-crash technology installed on the aircraft. The plaintiffs alleged that the technology had design and manufacturing defects and that they were decisive factors in causing the accident. The Supreme Court upheld the decision of the lower court, finding the defendant companies liable and ordering them to pay the victims over €600 million in compensation.

Most recently, the Court of Appeal of Madrid upheld an appeal filed by the manufacturer of the banned pregnancy drug thalidomide against a decision of a court of first instance in Madrid that ordered the appellant to pay a significant amount in compensation to several people who were born with birth defects in the 1960s. In its decision, the Court of Appeal of Madrid accepted the statute of limitation defences that the manufacturer had argued to refute its liability, which was recently confirmed by the Supreme Court.

In general, the increase of product safety standards and the severity of legal consequences (the putting into circulation of unsafe products for consumption might be a criminal offence under certain circumstances) have caused an increase in awareness among producers and distributors on the need to monitor product safety. As a result, product recalls have grown significantly in Spain during the past decade.
ABOUT THE AUTHORS

ALEX FERRERES COMELLA

Uría Menéndez

Alejandro Ferreres Comella is a partner of Uría Menéndez and the head of the litigation and arbitration practice areas of the Barcelona offices of the firm.

He is a practising litigator in the jurisdictions of Madrid and Barcelona, among others, and concentrates his practice in the areas of contractual liability and tort. In particular, he has taken part in the defence of car manufacturers, pharmaceutical companies, tobacco companies and the chemical industry in some of the most important product liability cases in Spain, including several collective claims.

He is considered a leading lawyer in the main international legal directories by Chambers and Partners and Who’s Who Legal, among others.

CRISTINA AYO FERRÁNDIZ

Uría Menéndez

Cristina Ayo Ferrándiz is a member of the litigation practice area of Uría Menéndez’s Barcelona office. She joined the firm in September 2000, and became a counsel in January 2013.

She focuses her practice on advising on contentious and pre-contentious civil and commercial issues. Ms Ayo specialises in judicial proceedings before the Spanish courts and tribunals and national and international arbitration proceedings relating to contractual liability, non-contractual liability and product liability, as well as contractual, corporate, lease agreements, banking, financial and private party disputes.

URÍA MENÉNDEZ

Av Diagonal 514
08006 Barcelona
Spain
Tel: +34 93 416 51 00
Fax: +34 93 416 51 11
alex.ferreres@uria.com
cristina.ayo@uria.com
www.uria.com